362 related articles for article (PubMed ID: 27140693)
1. The impact of metabotropic glutamate receptors into active neurodegenerative processes: A "dark side" in the development of new symptomatic treatments for neurologic and psychiatric disorders.
Bruno V; Caraci F; Copani A; Matrisciano F; Nicoletti F; Battaglia G
Neuropharmacology; 2017 Mar; 115():180-192. PubMed ID: 27140693
[TBL] [Abstract][Full Text] [Related]
2. Metabotropic glutamate receptors as therapeutic targets in Parkinson's disease: An update from the last 5 years of research.
Litim N; Morissette M; Di Paolo T
Neuropharmacology; 2017 Mar; 115():166-179. PubMed ID: 27055772
[TBL] [Abstract][Full Text] [Related]
3. Neuroprotective and symptomatic effects of targeting group III mGlu receptors in neurodegenerative disease.
Williams CJ; Dexter DT
J Neurochem; 2014 Apr; 129(1):4-20. PubMed ID: 24224472
[TBL] [Abstract][Full Text] [Related]
4. Group III and subtype 4 metabotropic glutamate receptor agonists: discovery and pathophysiological applications in Parkinson's disease.
Amalric M; Lopez S; Goudet C; Fisone G; Battaglia G; Nicoletti F; Pin JP; Acher FC
Neuropharmacology; 2013 Mar; 66():53-64. PubMed ID: 22664304
[TBL] [Abstract][Full Text] [Related]
5. Metabotropic glutamate receptors: potential drug targets for the treatment of schizophrenia.
Chavez-Noriega LE; Schaffhauser H; Campbell UC
Curr Drug Targets CNS Neurol Disord; 2002 Jun; 1(3):261-81. PubMed ID: 12769619
[TBL] [Abstract][Full Text] [Related]
6. [Metabotropic glutamate receptors as targets for new drug development].
Arkhipov VI; Kapralova MV
Eksp Klin Farmakol; 2011; 74(10):46-52. PubMed ID: 22238988
[TBL] [Abstract][Full Text] [Related]
7. Metabotropic glutamate receptor subtypes as targets for neuroprotective drugs.
Bruno V; Battaglia G; Copani A; D'Onofrio M; Di Iorio P; De Blasi A; Melchiorri D; Flor PJ; Nicoletti F
J Cereb Blood Flow Metab; 2001 Sep; 21(9):1013-33. PubMed ID: 11524608
[TBL] [Abstract][Full Text] [Related]
8. Targeting metabotropic glutamate receptors for novel treatments of schizophrenia.
Maksymetz J; Moran SP; Conn PJ
Mol Brain; 2017 Apr; 10(1):15. PubMed ID: 28446243
[TBL] [Abstract][Full Text] [Related]
9. Metabotropic glutamate receptors in neurodegeneration/neuroprotection: still a hot topic?
Caraci F; Battaglia G; Sortino MA; Spampinato S; Molinaro G; Copani A; Nicoletti F; Bruno V
Neurochem Int; 2012 Sep; 61(4):559-65. PubMed ID: 22306345
[TBL] [Abstract][Full Text] [Related]
10. Targeting group II metabotropic glutamate (mGlu) receptors for the treatment of psychosis associated with Alzheimer's disease: selective activation of mGlu2 receptors amplifies beta-amyloid toxicity in cultured neurons, whereas dual activation of mGlu2 and mGlu3 receptors is neuroprotective.
Caraci F; Molinaro G; Battaglia G; Giuffrida ML; Riozzi B; Traficante A; Bruno V; Cannella M; Merlo S; Wang X; Heinz BA; Nisenbaum ES; Britton TC; Drago F; Sortino MA; Copani A; Nicoletti F
Mol Pharmacol; 2011 Mar; 79(3):618-26. PubMed ID: 21159998
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological profiling of native group II metabotropic glutamate receptors in primary cortical neuronal cultures using a FLIPR.
Sanger H; Hanna L; Colvin EM; Grubisha O; Ursu D; Heinz BA; Findlay JD; Vivier RG; Sher E; Lodge D; Monn JA; Broad LM
Neuropharmacology; 2013 Mar; 66():264-73. PubMed ID: 22659090
[TBL] [Abstract][Full Text] [Related]
12. Molecular pharmacology and therapeutic prospects of metabotropic glutamate receptor allosteric modulators.
Ritzén A; Mathiesen JM; Thomsen C
Basic Clin Pharmacol Toxicol; 2005 Oct; 97(4):202-13. PubMed ID: 16176554
[TBL] [Abstract][Full Text] [Related]
13. Allosteric modulators of group I metabotropic glutamate receptors: novel subtype-selective ligands and therapeutic perspectives.
Gasparini F; Kuhn R; Pin JP
Curr Opin Pharmacol; 2002 Feb; 2(1):43-9. PubMed ID: 11786307
[TBL] [Abstract][Full Text] [Related]
14. Biased allosteric agonism and modulation of metabotropic glutamate receptor 5: Implications for optimizing preclinical neuroscience drug discovery.
Sengmany K; Singh J; Stewart GD; Conn PJ; Christopoulos A; Gregory KJ
Neuropharmacology; 2017 Mar; 115():60-72. PubMed ID: 27392634
[TBL] [Abstract][Full Text] [Related]
15. [Metabotropic glutamate receptors: new molecular targets in the treatment of neurological and psychiatric diseases].
Luján-Miras R
Rev Neurol; 2005 Jan 1-15; 40(1):43-53. PubMed ID: 15696426
[TBL] [Abstract][Full Text] [Related]
16. Metabotropic glutamate receptor 4 (mGlu4)-positive allosteric modulators for the treatment of Parkinson's disease: historical perspective and review of the patent literature.
Lindsley CW; Hopkins CR
Expert Opin Ther Pat; 2012 May; 22(5):461-81. PubMed ID: 22506633
[TBL] [Abstract][Full Text] [Related]
17. In vitro pharmacological and rat pharmacokinetic characterization of LY3020371, a potent and selective mGlu
Witkin JM; Ornstein PL; Mitch CH; Li R; Smith SC; Heinz BA; Wang XS; Xiang C; Carter JH; Anderson WH; Li X; Broad LM; Pasqui F; Fitzjohn SM; Sanger HE; Smith JL; Catlow J; Swanson S; Monn JA
Neuropharmacology; 2017 Mar; 115():100-114. PubMed ID: 26748052
[TBL] [Abstract][Full Text] [Related]
18. Group II metabotropic glutamate receptor agonists as a potential drug for schizophrenia.
Chaki S
Eur J Pharmacol; 2010 Aug; 639(1-3):59-66. PubMed ID: 20371240
[TBL] [Abstract][Full Text] [Related]
19. Recent Developments in Group I Metabotropic Glutamate Receptor Allosteric Modulators for the Treatment of Psychiatric and Neurological Disorders (2014-May 2015).
Li G; Jorgensen M; Campbell BM; Doller D
Curr Top Med Chem; 2016; 16(29):3470-3526. PubMed ID: 27048271
[TBL] [Abstract][Full Text] [Related]
20. Metabotropic glutamate mGlu1 receptor stimulation and blockade: therapeutic opportunities in psychiatric illness.
Lesage A; Steckler T
Eur J Pharmacol; 2010 Aug; 639(1-3):2-16. PubMed ID: 20371230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]